Coronavirus COVID-19
Palabras clave: América Latina | Coronavirus | COVID-19 | Diagnóstico | Epidemiología |
SARS-CoV-2 | Tratamiento | Síntomas | Vacunas |
Información destacada

Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
ABSTRACT Background: Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at studying

Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022
ABSTRACT Background: Despite bacterial coinfection rates of less than 10%, antibiotics are prescribed to an estimated 75% of patients with COVID-19, potentially exacerbating antimicrobial resistance.

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
ABSTRACT Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative regimen is yet available, therefore patients are forced to rely on